{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/64d53bc8af8fd800117b9642/67e17d09a7645568bd763ee1?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AstraZeneca to invest $2.5 billion in China research and development hub","description":"<p>Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China-based research – plus the company’s first vaccine-manufacturing facility in the country.</p><p><br></p><p>The British-Swedish drug maker, which saw one of its executives detained in China last year, announced a multibillion-dollar investment deal last week, before its CEO attended a global business forum in Beijing.</p><p>AstraZeneca inked a US$2.5 billion contract with the city government of Beijing to establish the firm’s sixth global strategic R&amp;D centre, with high-end industrialisation projects conducted in the Chinese capital to advance life sciences throughout the country.</p>","author_name":"Daily SumUp"}